Verastem Oncology Names John Hayslip as Chief Medical Officer

Dow Jones04-19

By Paul Ziobro

Verastem Oncology named John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the biopharmaceutical company.

Hayslip has more than 25 years of oncology and research and development experience. He most recently served as chief medical officer at I-MAB Biopharma.

Prior to that, he was vice president of clinical development at Nektar Therapeutics and led clinical develop activities for multiple therapies at AbbVie Oncology.

Based in Boston, Verastem is a late-stage biopharmaceutical company developing focused on developing medicine for cancer patients.

Hayslip will lead development programs for Verastem's cancer treatment avutometinib.

Write to Paul Ziobro at paul.ziobro@wsj.com

(END) Dow Jones Newswires

April 18, 2024 16:27 ET (20:27 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2428542961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-04-19 04:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428542961","market":"fut","top_or_hot":-1,"title":"Verastem Oncology Names John Hayslip as Chief Medical Officer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Paul Ziobro \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology named John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the biopharmaceutical company. \n</p>\n<p>\n  Hayslip has more than 25 years of oncology and research and development experience. He most recently served as chief medical officer at I-MAB Biopharma. \n</p>\n<p>\n  Prior to that, he was vice president of clinical development at Nektar <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and led clinical develop activities for multiple therapies at AbbVie Oncology. \n</p>\n<p>\n  Based in Boston, Verastem is a late-stage biopharmaceutical company developing focused on developing medicine for cancer patients. \n</p>\n<p>\n  Hayslip will lead development programs for Verastem's cancer treatment avutometinib. \n</p>\n<p>\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 18, 2024 16:27 ET (20:27 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Oncology Names John Hayslip as Chief Medical Officer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Oncology Names John Hayslip as Chief Medical Officer\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-19 04:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Paul Ziobro \n\n\nVerastem Oncology named John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the biopharmaceutical company. \n\n\n  Hayslip has more than 25 years of ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2428542961","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428542961","pubTimestamp":1713472020,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology named John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the biopharmaceutical company.Hayslip has more than 25 years of oncology and research and development experience. He most recently served as chief medical officer at I-MAB Biopharma.Prior to that, he was vice president of clinical development at Nektar Therapeutics and led clinical develop activities for multiple therapies at AbbVie Oncology.Based in Boston, Verastem is a late-stage biopharmaceutical company developing focused on developing medicine for cancer patients.Hayslip will lead development programs for Verastem's cancer treatment avutometinib.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VSTM":"Verastem"},"translate_title":"Verastem Oncology任命John Hayslip为首席医疗官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1},"content_text":"By Paul Ziobro \n\n\nVerastem Oncology named John Hayslip as chief medical officer, succeeding Louis Denis, who recently left the biopharmaceutical company. \n\n\n  Hayslip has more than 25 years of oncology and research and development experience. He most recently served as chief medical officer at I-MAB Biopharma. \n\n\n  Prior to that, he was vice president of clinical development at Nektar Therapeutics and led clinical develop activities for multiple therapies at AbbVie Oncology. \n\n\n  Based in Boston, Verastem is a late-stage biopharmaceutical company developing focused on developing medicine for cancer patients. \n\n\n  Hayslip will lead development programs for Verastem's cancer treatment avutometinib. \n\n\n  Write to Paul Ziobro at paul.ziobro@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 18, 2024 16:27 ET (20:27 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428542961"}